Pete Gough
Head of Research, Immuno-Pharmacology & Peptide Discovery Abbvie
Pete Gough is the Head of Immuno-Pharmacology and Peptide Discovery a Abbvie and was previously the CSO at Nimble Therapeutics prior to their acquisition by Abbvie at the beginning of 2025. He has spent over 20 years in Pharma/Biotech with a proven track record of driving innovative drug programs into the clinic.
Seminars
Wednesday 29th April 2026
Peptide Industry Leaders’ Discussion – Unlocking Next Frontiers of Bioavailable Peptide-Based Therapeutics to Patients Faster
9:15 am
This your chance to hear from pioneering executive leaders the peptide space who will discuss their ambitions, strategies and challenges for peptide discovery, targets. indications and development of next generation of peptide drugs.
Key questions to be addressed include:
- What are the future opportunities, promising targets and applications on the horizon for peptide-drugs to achieve the next best in-market approval?
- Where is the next big wave heading after GLP-1 peptides?
- How will peptide-drugs compete against the biologics, antibody and small molecule markets as standards of care?
